Effect of esmolol on prevention of atrial fibrillation after coronary artery bypass grafting: a randomised, double-blinded, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036275

Enrollment

Unknown

Registered

2020-08-22

Start date

2021-04-01

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-operative atrial fibrillation

Interventions

Experimental group:receiving intravenous esmolol hydrochloride

Control group:receiving intravenous 0.9% normal saline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged >=18 years. 2) Undergoing off-pump coronary artery bypass grafting. 3) Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Pre-operative history of atrial fibrillation. 2) Redo cardiac surgery. 3) New York Heart Association (NYHA) heart function classification III to IV. 4) Left ventricular ejection fraction (LVEF) < 40%. 5) Sinus bradycardia (resting heart rate < 60 beats per minute). 6) Second or third degree atrioventricular block. 7) Taking class I or III antiarrhythmic agents. 8) Bronchial asthma or a history of asthma. 9) Symptomatic chronic obstructive pulmonary disease. 10) Pregnancy. 11) Allergy to esmolol or known intolerance.

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation;	—

Secondary

Measure	Time frame
30-day mortality;Heart rate;Systolic blood pressure;Mean blood pressure;Length of stay-ICU;Hospitalization costs;Serum biomarkers;	—

Countries

China

Contacts

Public ContactBo Xie

Renji Hospital, Shanghai Jiaotong University School of Medicine

xieborj@hotmail.com+86 13916228344

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026